NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

dennisdave,

The $600,000,000+ money set aside in the UK is for access to treatments like L after approval but before final reimbursement agreement. So I agree that approval and the journal article will be tied closely together and then at that point the Specials program opens up the floodgates. Remember that MHRA approval is based on the commercial manufacturing license which is expected by year end and we know the MAA submission or acceptance could be announced sooner but not approved until Advent gets that license. Advent will get er done on time or before. Kind of a Cambridge reputation thing ; ). Best wishes.